Claims

1. Glucocorticoid (GC) for use in a method of amelioration, treatment or prophylaxis of neurological adverse events caused by the administration of a CD3 binding domain, wherein the GC is to be administered prior to the administration of the first dose of the CD3 binding domain and prior to the administration of the second dose and/or third dose of the CD3 binding domain.

2. The glucocorticoid for the use of claim 1, wherein said GC is dexamethasone.

3. The glucocorticoid for the use of any of the preceding claims, wherein a first dose of the CD3 binding domain is to be administered for a first period of time and consecutively a second dose of the CD3 binding domain is to be administered for a second period of time, wherein the second dose exceeds the first dose.

4. The glucocorticoid for the use of claim 3, wherein after a first and second dose of the CD3 binding domain for a first and second period of time, a third dose of the CD3 binding domain is to be administered, wherein the third dose exceeds the first and second dose.

5. The glucocorticoid for the use of claim 1 or 2, wherein the CD3 binding domain is to be administered continuously.

6. The glucocorticoid for the use of any one of the preceding claims, wherein said neurological adverse event is one or more of disturbances of the senses, seizures, encephalopathy, cerebral edema, confusion, ataxia, apraxia, speech disorder, hallucinations, paresis, tremor, headache or disorientation.

7. The glucocorticoid for the use any one of the preceding claims, wherein the GC is to be administered subsequent to the appearance of the neurological adverse event.

8. The glucocorticoid for the use of any one of the preceding claims, wherein said CD3 binding domain is a bispecific single chain antibody.

9. The glucocorticoid for the use of claim 8, wherein said bispecific single chain antibody is a CD19 x CD3 bispecific single chain antibody.

10. The glucocorticoid for the use of claim 9, wherein said CD19 x CD3 bispecific single chain antibody is MT103.

11. The glucocorticoid for the use of any one of the preceding claims, wherein said patient is a human.

12. The glucocorticoid for the use of any one of the preceding claims, wherein said patient is characterized by a B/Tcellratio of less than 1:5.

13. The glucocorticoid for the use of any one of claims 1 to 12, wherein said CD3 binding domain binds to human CD3 epsilon.